When Enthusiasm for New Cancer Drugs Is Premature

Bishal Gyawali

Interview in Oncology Times, 04/08/2021

Bishal Gyawali, MD, PhD, VIVIO clinical team member, interviewed. According to Gyawali, “what’s the point in having a drug that does not reach patients because of unaffordability? Both high cost and low probability of clinical benefit should make us question the value of a drug, not hail it as a game-changer.”